How is cervical intraepithelial neoplasia grade 1 (CIN 1) treated?

Cervical intraepithelial neoplasia grade 1 (CIN 1) represents a mild, low-grade precancerous change in the cells of the cervix—often associated with transient human papillomavirus (HPV) infection. In most cases (approximately 60–80%), CIN 1 spontaneously regresses within 12 to 24 months without intervention, particularly in immunocompetent individuals under age 30. Therefore, the standard initial management is conservative: expectant observation with repeat cytology (Pap smear) and/or HPV testing at 6- to 12-month intervals, or colposcopy with biopsy as clinically indicated. Treatment—such as excisional procedures (e.g., loop electrosurgical excision procedure [LEEP]) or ablative methods (e.g., cryotherapy or laser ablation)—is generally reserved for persistent CIN 1 lasting more than two years, recurrent lesions, or cases where higher-grade disease cannot be confidently excluded due to inadequate colposcopic visualization or sampling. Management decisions must be individualized, incorporating factors such as patient age, reproductive plans, immunocompetence, HPV genotype (especially high-risk types like HPV 16/18), and histologic certainty. Close follow-up remains essential regardless of initial strategy, as progression—though uncommon—is possible.